dc.contributor.author | Standaert, David G. | |
dc.contributor.author | Aldred, Jason | |
dc.contributor.author | Anca-Herschkovitsch, Marieta | |
dc.contributor.author | Bourgeois, Paul | |
dc.contributor.author | Cubo Delgado, Esther | |
dc.contributor.author | Davis, Thomas L. | |
dc.contributor.author | Iansek, Robert | |
dc.contributor.author | Kovács, Norbert | |
dc.contributor.author | Pontieri, Francesco E. | |
dc.contributor.author | Siddiqui, Mustafa S. | |
dc.contributor.author | Simu, Mihaela | |
dc.contributor.author | Bergmann, Lars | |
dc.contributor.author | Kukreja, Pavnit | |
dc.contributor.author | Robieson, Weining | |
dc.contributor.author | Chaudhuri, K. Ray | |
dc.date.accessioned | 2024-03-12T13:20:52Z | |
dc.date.available | 2024-03-12T13:20:52Z | |
dc.date.issued | 2021-05 | |
dc.identifier.issn | 2330-1619 | |
dc.identifier.uri | http://hdl.handle.net/10259/8812 | |
dc.description.abstract | Background:Levodopa-carbidopa intestinal gel (LCIG) is an established treatment for improvingmotor and some non-motor symptoms (NMS) in patients with advanced Parkinson’s disease (PD). Prospectivelong-term data in routine clinical practice are limited.ObjectiveObjective:Assess LCIG effectiveness and safety in patients with advanced PD after 12 months during real-worldroutine clinical practice.MethodsMethods:Duodopa/Duopa in patients with advanced Parkinson’s disease—a global observational studyevaluating long-term effectiveness (DUOGLOBE) (NCT02611713) is an ongoing, prospective, multinational,observational study of LCIG-naïve patients treated as part of routine clinical practice; 3 years of follow-up areplanned. The primary outcome is the change in patient-reportedofftime. Other assessments include theUnified Dyskinesia Rating Scale (UDysRS), Non-Motor Symptoms Scale (NMSS), Parkinson’s Disease Sleep scale(PDSS-2), Epworth Sleepiness Scale (ESS), health-related quality of life (HR-QoL), caregiver burden, and seriousadverse events (SAEs). Outcomes from baseline to month (M) 12 are presented.ResultsResults:In this 12-month follow-up, patients (N=195) had baseline characteristics similar to other LCIG studies.Significant improvements (mean change to M12) were observed inofftime ( 3.9 3.6 hr/day,P< 0.001),dyskinesia assessed using the UDysRS ( 9.6 22.5,P< 0.001), NMSS ( 23.1 41.4,P< 0.001), sleep andsleepiness symptoms on the PDSS-2 ( 6.5 12.2,P< 0.001) and ESS ( 1.0 5.7,P< 0.05), HR-QoL ( 9.0 21.6,P< 0.001), and caregiver burden ( 1.9 6.7,P=0.008). Overall, 40.5% (n=79) of patients experienced SAEs;fall (n=6; 3.1%) and urinary tract infection (n=6; 3.1%) were SAEs reported in≥3% of patients.ConclusionsConclusions:These 12-month outcome data show sustained, long-term improvements and support the real-world effectiveness of LCIG in patients with advanced PD. Safety was consistent with previous studies. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | es |
dc.publisher | International Parkinson and Movement Disorder Society | en |
dc.relation.ispartof | Movement Disorders Clinical Practice. 2021, V. 8, n. 7, p. 1061-1074 | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | DUOGLOBE | en |
dc.subject | Parkinson’s disease | en |
dc.subject | Levodopa-carbidopa intestinal gel | en |
dc.subject | Dyskinesia | en |
dc.subject | Real-world data | en |
dc.subject.other | Sistema nervioso-Enfermedades | es |
dc.subject.other | Nervous system-Diseases | en |
dc.subject.other | Medicina | es |
dc.subject.other | Medicine | en |
dc.subject.other | Neurología | es |
dc.subject.other | Neurology | en |
dc.title | DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease | en |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.relation.publisherversion | https://doi.org/10.1002/mdc3.13239 | es |
dc.identifier.doi | 10.1002/mdc3.13239 | |
dc.identifier.essn | 2330-1619 | |
dc.journal.title | Movement Disorders Clinical Practice | en |
dc.volume.number | 8 | es |
dc.issue.number | 7 | es |
dc.page.initial | 1061 | es |
dc.page.final | 1074 | es |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |